These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 28280299)

  • 1. A practical guide about biosimilar data for health care providers treating inflammatory diseases.
    Markenson J; Alvarez DF; Jacobs I; Kirchhoff C
    Biologics; 2017; 11():13-21. PubMed ID: 28280299
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biosimilars Have Arrived: Rituximab.
    Greenwald M; Tesser J; Sewell KL
    Arthritis; 2018; 2018():3762864. PubMed ID: 29765782
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biosimilars: impact of biologic product life cycle and European experience on the regulatory trajectory in the United States.
    Ahmed I; Kaspar B; Sharma U
    Clin Ther; 2012 Feb; 34(2):400-19. PubMed ID: 22244050
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biosimilars and the extrapolation of indications for inflammatory conditions.
    Tesser JR; Furst DE; Jacobs I
    Biologics; 2017; 11():5-11. PubMed ID: 28255229
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The totality of evidence approach in the development of AVT02 (adalimumab), a biosimilar to Humira.
    McClellan JE; Ómarsdóttir S; Roy N; Berger V; Michel C; Berti F
    Ther Adv Chronic Dis; 2024; 15():20406223231223286. PubMed ID: 38250743
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biosimilars: Practical Considerations for Pharmacists.
    Stevenson JG; Popovian R; Jacobs I; Hurst S; Shane LG
    Ann Pharmacother; 2017 Jul; 51(7):590-602. PubMed ID: 28176529
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Safety Outcomes for Originator TNF Inhibitors and Biosimilars in Rheumatoid Arthritis and Psoriasis Trials: A Systematic Literature Review.
    Moots RJ; Curiale C; Petersel D; Rolland C; Jones H; Mysler E
    BioDrugs; 2018 Jun; 32(3):193-199. PubMed ID: 29790131
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Language of Biosimilars: Clarification, Definitions, and Regulatory Aspects.
    Declerck P; Danesi R; Petersel D; Jacobs I
    Drugs; 2017 Apr; 77(6):671-677. PubMed ID: 28258517
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of biosimilars.
    Al-Sabbagh A; Olech E; McClellan JE; Kirchhoff CF
    Semin Arthritis Rheum; 2016 Apr; 45(5 Suppl):S11-8. PubMed ID: 26947440
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extrapolation and Interchangeability of Infliximab and Adalimumab in Inflammatory Bowel Disease.
    Chang S; Hanauer S
    Curr Treat Options Gastroenterol; 2017 Mar; 15(1):53-70. PubMed ID: 28164249
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biosimilars in ulcerative colitis: When and for who?
    Ilias A; Gonczi L; Kurti Z; Lakatos PL
    Best Pract Res Clin Gastroenterol; 2018; 32-33():35-42. PubMed ID: 30060937
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Statistical Primer on Biosimilar Clinical Development.
    Isakov L; Jin B; Jacobs IA
    Am J Ther; 2016; 23(6):e1903-e1910. PubMed ID: 26766293
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Understanding the Role of Comparative Clinical Studies in the Development of Oncology Biosimilars.
    Stebbing J; Mainwaring PN; Curigliano G; Pegram M; Latymer M; Bair AH; Rugo HS
    J Clin Oncol; 2020 Apr; 38(10):1070-1080. PubMed ID: 32058846
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biosimilars-Emerging Role in Nephrology.
    Wish JB
    Clin J Am Soc Nephrol; 2019 Sep; 14(9):1391-1398. PubMed ID: 30082337
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Experience with Biosimilars of Infliximab in Inflammatory Bowel Disease.
    Avila-Ribeiro P; Fiorino G; Danese S
    Curr Pharm Des; 2017; 23(44):6759-6769. PubMed ID: 29205114
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-Term Real-World Post-approval Safety Data of Multiple Biosimilars from One Marketing-Authorization Holder After More than 18 Years Since Their First Biosimilar Launch.
    Sagi S; Anjaneya P; Kalsekar S; Kottke A; Cohen HP
    Drug Saf; 2023 Dec; 46(12):1391-1404. PubMed ID: 37902937
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical and regulatory perspectives on biosimilar therapies and intended copies of biologics in rheumatology.
    Mysler E; Pineda C; Horiuchi T; Singh E; Mahgoub E; Coindreau J; Jacobs I
    Rheumatol Int; 2016 May; 36(5):613-25. PubMed ID: 26920148
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biosimilars: Rationale and current regulatory landscape.
    Olech E
    Semin Arthritis Rheum; 2016 Apr; 45(5 Suppl):S1-10. PubMed ID: 26947438
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Progress in biosimilar monoclonal antibody development: the infliximab biosimilar CT-P13 in the treatment of rheumatic diseases.
    Braun J; Kudrin A
    Immunotherapy; 2015; 7(2):73-87. PubMed ID: 25713985
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.